Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
Letter From The Editor

I am sure many of you have received an email or Facebook post to participate in the ALS Ice Bucket Challenge. I am amazed by the number of people who will actually have a bucket of ice poured over their heads, yet will not take the time to check their glucose levels or even take their diabetes medications. I was not the only one that found this to be interesting as Dr. Sheri Colberg also had some ideas about this and has come up with a way to make this work for her patients. Be sure to read this month's feature, The Challenge of Making Lifestyle Changes and Making Them Last.

Some of you may not have seen the announcement from the DEA last week but the decision has been made to reclassify all hydrocodone containing products to schedule 2. This means you will have to treat these drugs the same way you currently treat oxycodone and morphine. This will mean extra work for prescribers and pharmacists, and make it harder for your patients to get the pain relief they need. This is in response to the increasing abuse of these drugs by non-legitimate users. When I think of patients who use these medications for things like diabetic neuropathy it seems like we are going to have to develop a better system to ensure they get the help they need, but in the meantime you may want to read the item on the use of a vegan diet to improve diabetic neuropathy.



With a day packed full of education, motivational tools, one-on-one sessions, and workshops, the TCOYD health fair is a great way to get your patients to take better care of their health and themselves. 
From "Minding your manners over diabetes -- how to teach your friends and family boundaries that keep everyone happy. Then, Chef Michel Nischan serves up a diabetes-friendly Italian classic, and dLife visits Hardball's Chris Matthews." Sundays live online at at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at
We can make a difference!

Dave Joffe, Editor-in-chief

 … Read More

Scroll down for items in the current newsletter


New Basal Insulin Approved. See the Product of the Week.
New Test Approved to Diagnose Type 1 Diabetes. See this week's Facts.

Tool for your Practice

The Risk Calculator 

Predicting Risk for Developing Diabetes. Blood glucose levels measured in hospitalized patients during acute illness can be used to predict the risk of developing type 2 diabetes in the following three years. See this week's Item #6, BG Levels during Acute Illness Can Help Predict Future Diabetes Risk. The Risk Calculator 

Product of the Week

Basaglar (insulin glargine injection) by Lilly and Boehringer 

The FDA has granted tentative approval for Basaglar (insulin glargine injection), a basal insulin. Basaglar is Eli Lilly and Co. and Boehringer Ingelheim"s basal insulin. Basaglar has the same amino acid sequence as the currently marketed insulin glargine product. While the FDA has determined that Basaglar meets the regulatory requirements for approval, it is subject to an automatic stay of up to 30 months due to litigation filed by Sanofi, which claimed patent infringement. Due to the Drug Price Competition and Patent Term Restoration Act, the agency cannot grant final approval until the end of the 30-month period in mid-2016, unless the court finds in favor of Lilly before such time. 


The Challenge of Making Lifestyle Changes and Making Them Last

Print this out for all your patients!


By Sheri Colberg, PhD

I recently received an angry e-mail from someone I didn't know, and it really started me thinking about how to approach the challenge of making permanent lifestyle changes to manage diabetes and improve health.

In her e-mail "Irene" stated, "Your diabetes treatment advice to lose weight and exercise is not new. Telling people to lose weight and exercise is the cure for everything. I am tired of this advice from skinny women who were never overweight or lose weight easily due to the hormones they were born with. I was born fat with a hardy [her spelling of "hearty"] appetite, and due to a disability am not able to exercise."  Full Story....



Test Your Knowledge Question #743

Which of the following electrolyte abnormalities have been reported with SGLT-2 inhibitor therapy?

A. Hypokalemia
B. Hyperkalemia

C. Hypomagnesemia

D. Hyponatremia

For the complete question and answer, just follow this link.


Diabetes In Control Has Over 15000 Studies & Articles In Our Archives

Quote of the Week!

"Start where you are. Use what you have. Do what you can." 

              ................Arthur Ashe 


Diabetes in Control gratefully acknowledges the assistance of the following University of Florida pharmacy doctoral candidate in the preparation of this week's newsletter: 

Simi A. Lukose, 
Florida A&M University

Mai Do, Florida A&M University

Joanna Dam, LECOM College of Pharmacy 


Cast Your Vote
Do you recommend SGLT-2 drugs for type 1 diabetes?
CME/CE of the Week
John Steinberg, DPM

Category: Wound Care
Credits: .25


Search Articles On Diabetes In Control